LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
Clinical safety rating: safe
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP) to enhance insulin secretion and suppress glucagon. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
| Metabolism | Linagliptin: minimal metabolism, primarily excreted unchanged in feces via enterohepatic system (small contributions from CYP3A4). Metformin: not metabolized; excreted unchanged in urine. |
| Excretion | Linagliptin: ~85% fecal (biliary), ~5% renal; Metformin: 90-100% renal (unchanged). |
| Half-life | Linagliptin: 12-14 hours (terminal); Metformin: 6.2 hours (terminal). |
| Protein binding | Linagliptin: 70-80% (concentration-dependent, primarily to albumin); Metformin: negligible (0-5%). |
| Volume of Distribution | Linagliptin: 10-20 L (Vd); Metformin: 1-5 L/kg (Vd). |
| Bioavailability | Linagliptin: ~30% (oral); Metformin: 50-60% (oral, under fasting conditions). |
| Onset of Action | Linagliptin: 1-2 hours (oral, inhibition of DPP-4); Metformin: 2-3 hours (oral, reduction of hepatic glucose production). |
| Duration of Action | Linagliptin: >24 hours (once-daily dosing); Metformin: 12-24 hours (twice-daily dosing). |
| Molecular Weight | 672.92 |
Typical adult dose: one tablet containing linagliptin 2.5 mg and metformin hydrochloride 1000 mg orally twice daily with meals. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR < 30 mL/min/1.73 m². For eGFR 30-45: reduce metformin component to 500 mg twice daily; avoid initiating therapy. If eGFR falls below 30, discontinue. For eGFR 45-60: use caution; consider reducing metformin dose in patients at risk for lactic acidosis. |
| Liver impairment | Avoid use in patients with Child-Pugh class B or C hepatic impairment due to metformin-associated lactic acidosis risk. No specific dose adjustment is required for linagliptin in mild hepatic impairment; use caution if severe hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. Not recommended due to lack of data. |
| Geriatric use | Start with lower doses of metformin (e.g., 500 mg twice daily) in elderly patients, especially those >80 years, due to increased risk of lactic acidosis. Monitor renal function regularly; avoid if eGFR < 30 mL/min/1.73 m². No specific dose adjustment for linagliptin based on age alone, but use caution with declining renal function. |
| 1st trimester | Metformin crosses placenta; linagliptin minimal transfer. Limited human data: avoid unless benefit outweighs risk. |
| 2nd trimester | Metformin associated with low risk of malformations; linagliptin insufficient data. Use only if clearly needed. |
| 3rd trimester | Metformin may cause neonatal hypoglycemia; linagliptin unknown. Avoid in third trimester. |
Clinical note
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
| FDA category | Human |
| Placental transfer | Metformin actively crosses placenta via organic cation transporters; linagliptin minimal transfer in animal studies. |
| Breastfeeding |
■ FDA Black Box Warning
No black box warning for this combination; however, metformin has warnings for lactic acidosis (not a boxed warning in the US, but a boxed warning in some countries).
| Common Effects | Diarrhea |
| Serious Effects |
Renal disease with eGFR <30 mL/min/1.73 m²Acute or chronic metabolic acidosis (including diabetic ketoacidosis)Hypersensitivity to linagliptin or metforminAcute conditions that could alter renal function (e.g., dehydration, severe infection, shock)
| Precautions | Lactic acidosis risk (renal impairment, hypoxia, sepsis, alcohol use, hepatic impairment); discontinue if suspected, Pancreatitis (monitor for symptoms); hypersensitivity reactions; acute kidney injury; vitamin B12 deficiency with prolonged metformin use; hypoglycemia when used with insulin or sulfonylureas |
| Food/Dietary |
Loading safety data…
| Metformin is excreted into breast milk in low amounts; linagliptin excretion unknown. Monitor infant for hypoglycemia and gastrointestinal effects. Consider risks versus benefits. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Linagliptin: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Metformin: Generally considered low risk; some studies suggest possible association with preeclampsia and neonatal hypoglycemia, but not consistent malformations. In first trimester, metformin appears safe; second and third trimester risk may include increased abortion risk and potential fetal hypoglycemia. Overall, FDA category B for linagliptin and category B for metformin. |
| Fetal Monitoring | Monitor maternal renal function (serum creatinine, eGFR) at baseline and periodically due to metformin clearance. Assess glycemic control with HbA1c and blood glucose levels. During pregnancy, increased risk of lactic acidosis with metformin; monitor for symptoms (nausea, abdominal pain, hyperventilation). Fetal surveillance: growth scans for macrosomia or large-for-gestational-age, especially in diabetic pregnancies; consider serial ultrasounds. Monitor for hypoglycemia in neonate after delivery. |
| Fertility Effects | Linagliptin: No known direct effects on fertility; animal studies show no impairment. Metformin: May improve fertility in women with polycystic ovary syndrome (PCOS) by lowering insulin resistance and inducing ovulation. No negative impact on male fertility; some studies suggest improvement in PCOS-related infertility. Use during pregnancy planning may be beneficial in PCOS. |
| Take with meals to minimize metformin-related gastrointestinal adverse effects (nausea, diarrhea). Avoid excessive alcohol intake (≥3 drinks/day or binge drinking) due to increased risk of lactic acidosis with metformin. No specific food interactions for linagliptin. High-fat meals may affect absorption; take consistently with meals. Grapefruit juice has no known interaction. |
| Clinical Pearls | Combination DPP-4 inhibitor and biguanide. Linagliptin is primarily non-renal excreted (enterohepatic), so no dose adjustment in CKD; metformin requires monitoring of renal function (eGFR ≥30 mL/min/1.73 m² to avoid lactic acidosis). Avoid in acute HF or severe hepatic impairment. No significant CYP interactions; linagliptin is a weak P-gp inhibitor. Can cause pancreatitis; discontinue if suspected. Not associated with weight gain or hypoglycemia as monotherapy. Consider metformin GI intolerance; use extended-release formulation if needed. |
| Patient Advice | Take with meals to reduce stomach upset from metformin. · Do not drink excessive alcohol; can increase risk of lactic acidosis with metformin. · Monitor for symptoms of pancreatitis: severe abdominal pain with or without vomiting. · Contact healthcare provider if signs of lactic acidosis: unusual tiredness, muscle pain, trouble breathing, stomach discomfort with nausea/vomiting, or slow/irregular heartbeat. · Not used for type 1 diabetes or diabetic ketoacidosis. · Tell your doctor about all other medications, especially insulin, sulfonylureas, or drugs that affect kidney function. · Do not change dose or stop taking without consulting your doctor. · Report any allergic reactions: rash, hives, swelling of face/lips/tongue/throat, difficulty breathing. |